DBS Group Research analyst Rachel Tan has kept her ‘buy’ rating on IHH with an increased target price of $2.32 from $2.00 previously.
IHH is currently trading at a very attractive FY2022 EV/EBITDA of 14 times, close to -2 standard deviation of its historical range and is positioned to ride on the strong pent-up demand from foreign patients when borders reopen, says Tan.
Earlier on Jan 5, IHH announced that it has been in legal tussles with US fund Emqore Envesecure Private Capital Trust since June 2020.
For more insights on corporate trends...
Sign In or Create an account to access our premium content.
Subscription Entitlements:
Less than $9 per month
Unlimited access to latest and premium articles
3 Simultaneous logins across all devices
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
